These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 7448427)

  • 1. The growth fraction of human myeloma cells.
    Drewinko B; Alexanian R; Boyer H; Barlogie B; Rubinow SI
    Blood; 1981 Feb; 57(2):333-8. PubMed ID: 7448427
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expansion of the growth fraction in multiple myeloma with alkylating agents.
    Salmon SE
    Blood; 1975 Jan; 45(1):119-29. PubMed ID: 803104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor growth patterns in multiple myeloma.
    Hokanson JA; Brown BW; Thompson JR; Drewinko B; Alexanian R
    Cancer; 1977 Mar; 39(3):1077-84. PubMed ID: 912647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Growth kinetics of plasma cell myeloma.
    Drewinko B; Alexanian R
    J Natl Cancer Inst; 1977 May; 58(5):1247-53. PubMed ID: 857025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential therapy compared with combination therapy in multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):163-71. PubMed ID: 1111465
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors with high-dose melphalan for refractory multiple myeloma.
    Barlogie B; Alexanian R; Smallwood L; Cheson B; Dixon D; Dicke K; Cabanillas F
    Blood; 1988 Dec; 72(6):2015-9. PubMed ID: 3196876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission maintenance therapy for multiple myeloma.
    Arch Intern Med; 1975 Jan; 135(1):147-52. PubMed ID: 1111463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors in multiple myeloma.
    Alexanian R; Balcerzak S; Bonnet JD; Gehan EA; Haut A; Hewlett JS; Monto RW
    Cancer; 1975 Oct; 36(4):1192-201. PubMed ID: 1175123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Unmaintained remissions in multiple myeloma.
    Alexanian R; Gehan E; Haut A; Saiki J; Weick J
    Blood; 1978 Jun; 51(6):1005-11. PubMed ID: 647110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrosoureas in multiple myeloma.
    Salmon SE
    Cancer Treat Rep; 1976 Jun; 60(6):789-94. PubMed ID: 782701
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors.
    Jagannath S; Barlogie B; Dicke K; Alexanian R; Zagars G; Cheson B; Lemaistre FC; Smallwood L; Pruitt K; Dixon DO
    Blood; 1990 Nov; 76(9):1860-6. PubMed ID: 2224133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of tumor growth and regression in IgG multiple myeloma.
    Sullivan PW; Salmon SE
    J Clin Invest; 1972 Jul; 51(7):1697-708. PubMed ID: 5040867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human myeloma in vitro colony growth: interrelationships between drug sensitivity, cell kinetics, and patient survival duration.
    Durie BG; Young LA; Salmon SE
    Blood; 1983 May; 61(5):929-34. PubMed ID: 6831055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug resistance in multiple myeloma associated with high in vitro incorporation of 3H-thymidine.
    Hofmann V; Salmon SE; Durie BG
    Blood; 1981 Sep; 58(3):471-6. PubMed ID: 7259835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial.
    Mateos MV; Oriol A; Martínez-López J; Gutiérrez N; Teruel AI; de Paz R; García-Laraña J; Bengoechea E; Martín A; Mediavilla JD; Palomera L; de Arriba F; González Y; Hernández JM; Sureda A; Bello JL; Bargay J; Peñalver FJ; Ribera JM; Martín-Mateos ML; García-Sanz R; Cibeira MT; Ramos ML; Vidriales MB; Paiva B; Montalbán MA; Lahuerta JJ; Bladé J; Miguel JF
    Lancet Oncol; 2010 Oct; 11(10):934-41. PubMed ID: 20739218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. M-2 protocol for melphalan-resistant and relapsing multiple myeloma.
    Cavo M; Galieni P; Tassi C; Gobbi M; Tura S
    Eur J Haematol; 1988 Feb; 40(2):168-73. PubMed ID: 3345830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
    Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
    Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early plasma cell recruitment in multiple myeloma following chemotherapy.
    Ucci G; Riccardi A; Dörmer P; Danova M; Luoni R
    Cell Tissue Kinet; 1988 Nov; 21(6):405-9. PubMed ID: 3251633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone healing in multiple myeloma with melphalan chemotherapy.
    Rodriguez LH; Finkelstein JB; Shullenberger CC; Alexanian R
    Ann Intern Med; 1972 Apr; 76(4):551-6. PubMed ID: 4640313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.